127 related articles for article (PubMed ID: 35235952)
1. The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia.
Laidou S; Grigoriadis D; Papanikolaou S; Foutadakis S; Ntoufa S; Tsagiopoulou M; Vatsellas G; Anagnostopoulos A; Kouvatsi A; Stavroyianni N; Psomopoulos F; Makris AM; Agelopoulos M; Thanos D; Chatzidimitriou A; Papakonstantinou N; Stamatopoulos K
Blood Adv; 2022 Apr; 6(8):2646-2656. PubMed ID: 35235952
[TBL] [Abstract][Full Text] [Related]
2. Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.
Humphries LA; Godbersen JC; Danilova OV; Kaur P; Christensen BC; Danilov AV
Br J Haematol; 2013 Dec; 163(5):590-602. PubMed ID: 24117128
[TBL] [Abstract][Full Text] [Related]
3. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D; Beckmann L; Grimm C; Oliverio M; Meder L; Herling CD; Nieper P; Feldmann T; Merkel O; Lorsy E; da Palma Guerreiro A; von Jan J; Kisis I; Wasserburger E; Claasen J; Faitschuk-Meyer E; Altmüller J; Nürnberg P; Yang TP; Lienhard M; Herwig R; Kreuzer KA; Pallasch CP; Büttner R; Schäfer SC; Hartley J; Abken H; Peifer M; Kashkar H; Knittel G; Eichhorst B; Ullrich RT; Herling M; Reinhardt HC; Hallek M; Schweiger MR; Frenzel LP
Blood; 2022 Nov; 140(20):2113-2126. PubMed ID: 35704690
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
6. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription.
Buggins AG; Pepper C; Patten PE; Hewamana S; Gohil S; Moorhead J; Folarin N; Yallop D; Thomas NS; Mufti GJ; Fegan C; Devereux S
Cancer Res; 2010 Oct; 70(19):7523-33. PubMed ID: 20736369
[TBL] [Abstract][Full Text] [Related]
7. miR-15 and miR-16 induce apoptosis by targeting BCL2.
Cimmino A; Calin GA; Fabbri M; Iorio MV; Ferracin M; Shimizu M; Wojcik SE; Aqeilan RI; Zupo S; Dono M; Rassenti L; Alder H; Volinia S; Liu CG; Kipps TJ; Negrini M; Croce CM
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13944-9. PubMed ID: 16166262
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
9. Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N; Ntoufa S; Tsagiopoulou M; Moysiadis T; Bhoi S; Malousi A; Psomopoulos F; Mansouri L; Laidou S; Papazoglou D; Gounari M; Pasentsis K; Plevova K; Kuci-Emruli V; Duran-Ferrer M; Davis Z; Ek S; Rossi D; Gaidano G; Ritgen M; Oscier D; Stavroyianni N; Pospisilova S; Davi F; Ghia P; Hadzidimitriou A; Belessi C; Martin-Subero JI; Pott C; Rosenquist R; Stamatopoulos K
Int J Cancer; 2019 Jun; 144(11):2695-2706. PubMed ID: 30447004
[TBL] [Abstract][Full Text] [Related]
10. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
11. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
[TBL] [Abstract][Full Text] [Related]
12. TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
Koutroumani M; Laidou S; Kotta K; Stamatopoulos K
Leuk Lymphoma; 2021 Dec; 62(13):3288-3291. PubMed ID: 34323626
[No Abstract] [Full Text] [Related]
13. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Tam CS; Seymour JF; Roberts AW
Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
[TBL] [Abstract][Full Text] [Related]
14. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
16. The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker.
Papageorgiou SG; Kontos CK; Pappa V; Thomadaki H; Kontsioti F; Dervenoulas J; Papageorgiou E; Economopoulos T; Scorilas A
Oncologist; 2011; 16(9):1280-91. PubMed ID: 21737576
[TBL] [Abstract][Full Text] [Related]
17.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
18. BCL2 and miR-15/16: from gene discovery to treatment.
Pekarsky Y; Balatti V; Croce CM
Cell Death Differ; 2018 Jan; 25(1):21-26. PubMed ID: 28984869
[TBL] [Abstract][Full Text] [Related]
19. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.
Ougolkov AV; Bone ND; Fernandez-Zapico ME; Kay NE; Billadeau DD
Blood; 2007 Jul; 110(2):735-42. PubMed ID: 17463171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
